

CURRICULUM VITAE

LARA A. RAY, PhD
University of California, Los Angeles
3214 Franz Hall
Los Angeles, CA 90095
Phone: 310-794-5383
Email: lararay@psych.ucla.edu

ACADEMIC APPOINTMENTS

- Jul 2016 -** **Full Professor** (with tenure)
Department of Psychology (Clinical Area)
University of California, Los Angeles
- Jul 2013-Jun 2016** **Associate Professor** (with tenure)
Department of Psychology (Clinical Area)
University of California, Los Angeles
- Jul 2008-Jun 2013** **Assistant Professor**
Department of Psychology (Clinical Area)
University of California, Los Angeles
- Jul 2010 -** **Faculty Member**
Department of Psychiatry and Biobehavioral Sciences
School of Medicine
University of California, Los Angeles
- Mar 2009 -** **Faculty Member**
Brain Research Institute
University of California, Los Angeles
- Jul 2009 – Jun 2015** **Co-Director**
Addiction and Behavioral Medicine Clinic
UCLA Family Health Center
University of California, Los Angeles

EDUCATION

- Jul 2007-Jun 2008** **Postdoctoral Fellow**
Center for Alcohol and Addiction Studies
Brown University Medical School, Providence, Rhode Island
Specialty: Substance use disorders
- Jul 2006-Jun 2007** **Clinical Psychology Intern, Adult Track**
Brown University Medical School, Department of Psychiatry and Human Behavior,
Providence, Rhode Island

- Aug 2002-May 2007** **Doctor of Philosophy, Clinical Psychology**
University of Colorado at Boulder, Boulder, CO
Dissertation Title: *A double-blind placebo controlled study of the effects of naltrexone on alcohol sensitivity and genetic moderators of medication response*
- Aug 2002-Oct 2006** **Interdisciplinary Graduate Certificate, Behavioral Genetics**
Institute for Behavioral Genetics, University of Colorado at Boulder, Boulder, CO
- May 2004** **Master of Arts, Clinical Psychology**
University of Colorado at Boulder, Boulder, CO
Thesis Title: *A polymorphism of the μ -opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans*
- Aug 2001** **Bachelor of Arts, Psychology, with honors**
San Diego State University, San Diego, CA

HONORS AND AWARDS

- 2015** **Fellow**, American Psychological Association Division 50, Society of Addiction Psychology
- 2014** **Young Investigator Award**, Research Society on Alcoholism
- 2013** **Early Career Award for Distinguished Scientific Contributions**, APA Division 50, Society of Addiction Psychology
- 2013** **David Shakow Early Career Award for Distinguished Scientific Contributions to Clinical Psychology**, APA Division 12, Society of Clinical Psychology
- 2012** **Presentation Award**, NIDA-NIAAA Early Career Session, American Psychological Association, Division 50 (Addictions)
- 2011** **Travel Award**, International Behavioral and Neural Genetics Society (IBANGS)
- 2010** **Travel Award**, American College of Neuropsychopharmacology (ACNP)
- 2010** **NIAAA Travel Award**, International Society for Biomedical Research on Alcoholism
- 2009** **NIH Loan Repayment Program Award**, Competitive Renewal
- 2009** Winter Conference on Brain Research, **Travel Fellowship**
- 2008** First place winner of the **Early Career Presentation Award**, American Psychological Association, Division 50 (Addictions)
- 2008** **Young Investigator Award**, NIAAA-sponsored Conference on Alcoholism and Stress: A framework for Future Treatment Strategies. Volterra, Italy
- 2008** **Young Investigator Merit Award**, Research Society on Alcoholism Conference.
- 2007** **Dossier Award** for Outstanding Graduate Student Research, Department of Psychology, University of Colorado at Boulder
- 2007** **NIH Loan Repayment Program Award**
- 2007** **Psychology Intern Research Poster Award**, Department of Psychiatry and Human Behavior, Brown Medical School, 11th Annual Research Symposium
- 2007** Recipient of the **Enoch Gordis Research Award**, Research Society on Alcoholism
- 2007** **Student Merit Award**, Research Society on Alcoholism Conference
- 2006** **Student Merit Award**, Research Society on Alcoholism Conference
- 2005** Finalist for the **Enoch Gordis Research Award**, Research Society on Alcoholism
- 2005** **Student Merit Award**, Research Society on Alcoholism Conference
- 2005** **Alliance for Graduate Education and the Professoriate (AGEP) Travel Award**, University of Colorado at Boulder
- 2004** **Alliance for Graduate Education and the Professoriate (AGEP) Travel Award**, University of Colorado at Boulder
- 2004** **Student Merit Award**, Research Society on Alcoholism Conference.

2002-2003 Fellowship from the **National Science Foundation (NSF)** and the **Alliance for Graduate Education and the Professoriate (AGEP)**, University of Colorado at Boulder
2001 **Graduation with Distinction in Psychology**, San Diego State University
2000-2001 **Dean's Academic Honor List**, San Diego State University

PROFESSIONAL LICENSES

Oct 2008 **Licensed Clinical Psychologist**, California Board of Psychology,
License # 22240

Sep 2013 **Board Certification in Clinical Psychology**, American Board of Professional Psychology,
Diploma #7405

GRANT FUNDING

Active Research Support

<p>NIDA Combining varenicline and naltrexone for smoking cessation and drinking reduction This proposal is to conduct a randomized clinical trial comparing varenicline alone to varenicline plus naltrexone for smoking cessation in heavy drinking smokers. <u>Role:</u> PI</p>	<p>R01DA041226 TDC \$1,500,000</p>	<p>Ray (PI) Project Period: 9/1/2015-8/30/2018</p>
<p>NIH-NIDA Combining varenicline and naltrexone for smoking cessation and drinking reduction: Sex differences The purpose of this supplement is to examine the effect of sex as a marker of medication response. <u>Role:</u> PI</p>	<p>R01DA041226-02S1 (Supplement) TDC: \$99,766</p>	<p>Ray (PI) Project Period: 9/1/2015-5/31/2018</p>
<p>HHSN27500003-1061-NCIG6-UCLA Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of Gabapentin Enacarbil (Horizant®) Extended-Release Tablets for the Treatment of Alcohol Use Disorder This project is a randomized, multisite clinical trial comparing Horizant to placebo for the treatment of alcohol use disorders. <u>Role:</u> Co-PI</p>	<p>TDC \$792,295</p>	<p>Ray/Shoptaw (Co-PIs) Project Period: 3/1/2015-1/30/2017</p>
<p>NIAAA Perceived alcohol reward value and risk: Neural correlates and treatment effects This study will examine the effects of a brief intervention for alcohol use disorder on neural markers of the incentive salience of alcohol. <u>Role:</u> Co-PI</p>	<p>R21AA023669 TDC \$275,000</p>	<p>Ray/Karno (Co-PIs) Project Period: 4/1/2015-3/31/2017</p>
<p>TRDRP 18KT-0020 Therapeutic potential of oxytocin for nicotine addiction This project investigates the dose-dependent acute effects of intranasal oxytocin on socioemotional emotional processing disruptions, craving, and smoking lapse during tobacco withdrawal. <u>Role:</u> Co-I</p>	<p>TDC \$240,000</p>	<p>Kirkpatrick (PI) Project Period: 7/1/2016 – 6/30/2018</p>
<p>NIAAA Optimizing naltrexone for individuals of Asian descent The purpose of this study is to optimize the use of naltrexone for alcoholism on the basis of pharmacogenetics. <u>Role:</u> PI</p>	<p>R01AA021744 TDC \$750,000</p>	<p>Ray (PI) Project Period: 7/1/2013-6/30/2017 (NCE)</p>
<p>NIAAA</p>	<p>R21AA022752</p>	<p>Ray (PI)</p>

Modeling alcohol reward and reinforcement in the human laboratory

This study will test the association between subjective measures of alcohol reward and self-administration using state-of-the-art human laboratory paradigms.

Role: PI TDC \$275,000 Project Period: 9/10/2014-8/31/2017 (NCE)

Completed Research Support

NIAAA R01AA021744 (Diversity Supplement) Ray (PI)

Optimizing naltrexone for individuals of Asian descent

The purpose of this diversity supplement is to support the research training of a post-bac student from an underrepresented background and to help her achieve admission to a graduate program.

Role: PI/Mentor TDC \$70,588 Project Period: 9/01/2015-8/30/2016

NIAAA R34AA022055 Glassner-Edwards (PI)

Cell phone technology targeting ART and naltrexone adherence and alcohol use

This project uses mobile phone technology to deliver behavioral support for HIV-infected individuals with alcohol dependence treated with naltrexone.

Role: Co-I TDC \$450,000 Project Period: 7/01/2013-6/30/2016

NIAAA R21AA022214 Ray (PI)

Development of ibudilast as a novel treatment for alcohol dependence

This study consists of a series of human laboratory paradigms to test the initial efficacy of ibudilast, a glial cell modulator and phosphodiesterase inhibitor, for the treatment of alcoholism.

Role: PI TDC \$275,000 Project Period: 7/01/2013-6/30/2015

CTSI Seed Grant Ray (PI)

Repositioning ivermectin for the treatment of alcohol use disorders

This pilot study will examine safety and initial efficacy of ivermectin for the treatment of alcoholism.

Role: PI TDC \$157,199 Project Period: 9/01/2013-3/30/2015

NIDA R21 DA029831

Pharmacogenetics of naltrexone for methamphetamine use disorders

This study seeks to characterize the biobehavioral effects of naltrexone for methamphetamine use disorders and to extend its pharmacogenetics.

Role: PI TDC \$275,000 Project Period: 9/15/2011-08/31/2013

NIDA R21DA029831-01S1

Pharmacogenetics of naltrexone for methamphetamine use disorders (NIDA Summer Program Supplement)

The purpose of this supplement is to support three undergraduate students from underrepresented backgrounds to receive 10 weeks of research training in my research laboratory.

Role: PI/Mentor TDC \$30,000 Project Period: 6/25/12-8/24/12

NIDA R21DA029831-02S2

Pharmacogenetics of naltrexone for methamphetamine use disorders (NIDA Summer Program Supplement)

The purpose of this supplement is to support three undergraduate students from underrepresented backgrounds to receive 10 weeks of research training in my research laboratory.

Role: PI/Mentor TDC \$30,000 Project Period: 6/25/13-8/24/13

NIDA R03DA030898

Neuroimaging probes of medication response in smokers

The purpose of this project is to examine neural markers of response to a combined pharmacological treatment for heavy drinking smokers.

Role: PI TDC \$50,000 Project Period: 9/20/10-8/31/12

NIAAA R03AA19569

Integrating laboratory and neuroimaging phenotypes

The purpose of this project is to add a neuroimaging component to an ongoing laboratory study of subjective responses to alcohol and its underlying genetic determinants.

Role: PI TDC \$50,000 Project Period: 10/1/2009-9/30/2011

NIDA R03DA030898-01S1

Neuroimaging probes of medication response in smokers (NIDA Summer Program Supplement)

The purpose of this supplement is to support two undergraduate students from underrepresented backgrounds to receive 10 weeks of research training in my research laboratory.

Role: PI/Mentor TDC \$16,000 Project Period: 6/20/11-8/26/11

Hellman Fellowship UCLA

The effects of naltrexone on the reinforcing properties of methamphetamine in the brain

This pilot study will evaluate the effects of naltrexone, an opioid antagonist, on neural activation to methamphetamine versus control visual cues using an fMRI-based approach.

Role: PI TDC \$25,000 Project Period: 7/1/2011-6/30/2013

Faculty Research Grant UCLA Academic Senate

The effects of alcohol on fear conditioning in humans

The purpose of this study is to test a human laboratory model of fear conditioning combined with an alcohol administration protocol which will provide the context for the conditioning paradigm.

Role: PI TDC \$5,000 Project Period: 7/1/2011-6/30/2013

NIAAA R21 AA020573 Moore (PI)

Reducing unhealthy alcohol use in older Hispanic day laborers

The purpose of this application is to develop and test a culturally-adapted intervention to reduce hazardous alcohol use in Hispanic day laborers.

Role: Co-I TDC \$275,000 Project Period: 4/1/2011-03/31/2013

NIAAA R03AA020186 Lee (PI)

Prospective predictors of alcohol expectancies in children with and without ADHD

This project will prospectively examine the development of alcohol expectancies and alcohol use in children.

Role: Co-I TDC \$50,000 Project Period: 6/20/2010-8/26/12

TRDRP Shapiro (PI)

The effects of stereotype threat on smoking behavior

This project combines a stereotype threat manipulation with a human laboratory model of smoking and relapse. The goal is to examine the effects of stereotype threat on smoking behavior.

Role: Co-I TDC \$250,000 Project Period: 7/1/2011- 6/30/2013

Pfizer Global Award for Nicotine Dependence (GRAND)

The effects of varenicline on stress-induced and cue-induced cigarette craving: a placebo-controlled laboratory study

This study will examine the effects of varenicline versus placebo on stress and cue-induced craving for cigarettes as they affect the relative reinforcing value of cigarettes.

Role: PI TDC \$160,000 Project Period: 11/1/2010 to 10/30/2012

Tobacco Related Disease Research Program
Pharmacological interventions for heavy drinking smokers
The purpose of this project is to test the singular and combined effects of two medications (naltrexone and varenicline) for heavy drinking smokers in the laboratory.

TRDRP 18KT-0020

Role: PI TDC \$285,000 Project Period: 7/1/2009-6/30/2012

ABMRF, the Foundation for Alcohol Research
Integrating human laboratory paradigms to refine alcoholism phenotypes
The purpose of this study is to combine two human laboratory paradigms, intravenous alcohol administration and cue-exposure, to refine alcoholism phenotypes.

Role: PI TDC \$100,000 Project Period: 1/1/2009-6/30/2011

NIA P30AG021684
Brief intervention for alcohol misuse among elderly Latino day laborers
This pilot study will support initial survey and treatment development efforts designed to reduce risky alcohol use among Latino day laborers.

Role: Pilot project PI TDC \$20,000 Project Period: 9/20/10-8/31/11

M01-RR00865 National Institutes of Health/UCLA Clinical Research Center
Support for three alcohol administration and pharmacotherapy studies to be conducted at the UCLA General Clinical Research Center (GCRC); Protocols #1593, 1605, and 1611. Financial support in addition to the access to the GCRC facilities, laboratory, and nursing staff

Role: PI TDC \$50,000 Project Period: 7/1/2009-6/30/2012

Faculty Research Grant UCLA Academic Senate
Pharmacogenetics of naltrexone in Asian Americans
The purpose of this study is to extend findings of naltrexone pharmacogenetics in Caucasian samples to individuals of Asian descent.

Role: PI TDC \$10,000 Project Period: 7/1/2009-6/30/2010

NIAAA R21 AA017273-01 Miranda (PI)
Mechanisms of naltrexone's action on drinking in adolescents
The purpose of this study is to improve our understanding of the efficacy and mechanisms of naltrexone for adolescents with alcohol dependence.

Role: Co-I TDC \$10,000 Project Period: 7/1/2008-6/30/2010

NIAAA T32 AA007459-20 Spirito (PI) 7/01/2007-6/30/2008
Research Training in Alcohol Treatment and Early Intervention Research
The purpose of this postdoctoral grant is to train PhD and MD postdoctoral fellows to carry out independent research in the field of alcohol research. Role: Postdoctoral Research Fellow

NIAAA F31 AA014847 Ray (PI) 4/30/2004-3/30/2007
Genetic Correlates of Alcohol Use Disorders
This NRSA provided training in state of the art methods in genetic association studies and alcohol endophenotypes, including interdisciplinary training through the Institute for Behavioral Genetics at the University of Colorado at Boulder.

Dissertation Grant Ray (PI) 2005
Leadership Alliance/Schering-Plough Fellowship
A polymorphism of the μ -opioid receptor gene (OPRM1) and the effects of naltrexone on subjective responses to alcohol

Research Grant Ray (PI) 2003
 Beverly Sears Graduate Student Grant Award
 A polymorphism of the μ -opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans

Training grants to Dr. Ray's graduate students and post-doctoral fellows

NIAAA F32 AA023449 Yardley (PI)
 Clinical assessment of ivermectin as a therapeutic agent to reduce alcohol intake
Role: Sponsor TDC: \$49,850 Project: Period: 8/19/2014-8/18/2016

Postdoctoral Fellowship Award 309161 Roche (PI)
 California Tobacco-related Disease Research Program - Effects of varenicline in heavy drinking smokers
Role: Sponsor TDC: \$145,000 Project: Period: 8/01/2014-7/31/2017

NIDA F31 DA035604 Courtney (PI)
 The effects of naltrexone on neural responses to methamphetamine cues
Role: Sponsor TDC \$47,000 Project Period: 10/01/2013-9/30/2015

NIAAA F31 AA022569 Bujarski (PI)
 The interplay between subjective response and self-administration of alcohol in the human laboratory.
Role: Sponsor TDC \$47,000 Project Period: 4/01/2014-3/30/2016

PUBLICATIONS

Peer-Reviewed Publications

1. **Ray, L.A.**, & Hutchison, K. E. (2004). A polymorphism of the μ -opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcoholism Clinical and Experimental Research, 28, 1789-1795.
2. Fromme, K., de Witt, H., Hutchison, K.E., **Ray, L.A.**, Corbin, W.R., Cook, T.A., & Wall, T.L. (2004). Biological and behavioral markers of alcohol sensitivity. Alcoholism Clinical and Experimental Research, 28(2), 247-256.
3. Hines, L., **Ray, L.A.**, Hutchison, K.E., & Tabakoff, B. (2005). Alcoholism: The dissection for endophenotypes. Dialogues in Clinical Neuroscience, 7(3), 153-163.
4. Hutchison, K.E., **Ray, L.A.**, Sandman, E., Rutter, M.C., Peters, A., & Swift, R. (2006). The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology, 31, 1310-1317.
5. **Ray, L.A.**, McGeary, J., Marshall, E., & Hutchison, K.E. (2006). Risk factors for alcohol misuse: Examining heart rate response to alcohol, alcohol sensitivity, and personality constructs. Addictive Behaviors, 31(11), 1959-1973.
6. **Ray, L.A.**, Hutchison, K.E., & Bryan, A. (2006). Psychosocial predictors of treatment outcome, dropout, and change processes in a pharmacological clinical trial for alcohol dependence. Addictive Disorders and Their Treatment, 5(4), 179-190.
7. Bryan, A., **Ray, L.A.**, & Cooper, M.L. (2007). Alcohol use and protective sexual behaviors among high-risk adolescents: A prospective analysis. Journal of Studies on Alcohol and Drugs, 68(3), 327-335.
8. **Ray, L.A.**, Meskew-Stacer, S., & Hutchison, K.E. (2007). The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. Journal of Studies on Alcohol and Drugs, 68(3), 379-384.
9. **Ray, L.A.**, Rhee, S.H., Stallings, M.S., Knopik, V., & Hutchison, K.E. (2007). Examining the heritability of a laboratory-based smoking endophenotype: Initial Results from an experimental twin study. Twin Research and Human Genetics, 10(4), 546-553.

10. **Ray, L.A.**, Miranda, R. Jr., Kahler, C.M., Leventhal, A.M., Monti, P.M., Swift, R., & Hutchison, K.E. (2007). Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes: A pilot study. *Psychopharmacology*, *193*(4), 449-456.
11. **Ray, L.A.**, & Hutchison, K.E. (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study. *Archives of General Psychiatry*, *64*(9), 1069-1077.
12. **Ray, L.A.**, MacKillop, J., & Hutchison, K.E. (2007). Pharmacogenetics of the μ -opioid receptor and the treatment of addictions. *Personalized Medicine*, *4*(2), 217-220.
13. Miranda, R. Jr., Rohsenow, D.J., Monti, P.M., Tidey, J., & **Ray, L.A.** (2008). Effects of repeated days of smoking cue-exposure on urge to smoke and physiological reactivity. *Addictive Behaviors*, *33*(2), 347-353.
14. Miranda, R. Jr., MacKillop J., Monti, P.M., Rohsenow, D.J., Tidey, J., Gwaltney, C., Swift, R., **Ray, L.A.**, & McGeary, J.E. (2008). Effects of topiramate on urge to drink and the subjective effects of alcohol consumption. *Alcoholism Clinical and Experimental Research*, *32*(3), 489-497.
15. Leventhal, A.M., Kahler, C.W., **Ray, L.A.**, Stone, K., & Zimmerman, M. (2008). Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder. *American Journal on Addictions*, *17*(3), 218-223.
16. **Ray, L.A.**, Miranda Jr., R., Young, D., Chelminski, I., & Zimmerman, M. (2008). Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample. *Drug and Alcohol Dependence*, *96*(1-2), 187-191.
17. MacKillop, J., Murphy, J.G., **Ray, L.A.**, Eisenberg, D.T.A., Lisman, S.A., Lum, J.K., & Wilson, D.S. (2008). Further validation of the cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers. *Experimental and Clinical Psychopharmacology*, *16*(1), 57-65.
18. **Ray, L.A.**, Kahler, C., Young, D., Chelminski, I., & Zimmerman, M. (2008). The factor structure and severity of DSM-IV alcohol abuse and dependence symptoms in psychiatric outpatients. *Journal of Studies on Alcohol and Drugs*, *69*(4), 496-499.
19. **Ray, L.A.**, Hutchison, K.E., MacKillop, J., Miranda, R. Jr., Audette, A., Swift, R., & Monti, P.M. (2008). Effects of naltrexone during the descending limb of the blood alcohol curve. *American Journal on Addictions*, *17*(4), 257-264.
20. Haughey, H.M., **Ray, L.A.**, Finan, P., Villanueva, R., Nicolescu, M., & Hutchison, K.E. (2008). The Human GABA_A Receptor alpha 2 Gene Moderates the Acute Effects of Alcohol and Brain mRNA Expression. *Genes, Brain, and Behavior*, *7*(4), 447-454.
21. Filbey, F., **Ray, L.A.**, Smolen, A., Claus, E., Audette, A., & Hutchison, K.E. (2009). Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotype. *Alcoholism Clinical and Experimental Research*, *32*(7), 1113-1123.
22. **Ray, L.A.**, Bryan, A., MacKillop, J., McGeary, J., Hesterberg, K. & Hutchison, K.E. (2009). The Dopamine D4 receptor (DRD4) gene exon III polymorphism, problematic alcohol use, and novelty seeking: direct and mediated genetic effects. *Addiction Biology*, *14*(2), 238-244.
23. MacKillop, J., Murphy, J.G., Tidey, J., Kahler, C., **Ray, L.A.**, & Bickel, W. (2009). Latent structure of the facets of alcohol reinforcement from a behavioral economic demand curve. *Psychopharmacology*, *203*(1), 33-40.
24. **Ray, L.A.**, MacKillop, J., Leggio, L., Morgan, M., & Hutchison, K.E. (2009). Effects of naltrexone on cortisol levels in heavy drinkers. *Pharmacology, Biochemistry, and Behavior*, *91*, 489-494.
25. Leventhal, A.M., Kahler, C.W., **Ray, L.A.**, & Zimmerman, M. (2009). Refining the depression-nicotine dependence link: patterns of depressive symptoms in psychiatric outpatients with current, past, and no history of nicotine dependence. *Addictive Behaviors*, *34*(3), 297-303.
26. **Ray, L.A.**, Miranda, R., Jr., MacKillop, J., McGeary, J. E., Tidey, J. W., Rohsenow, D. J., Gwaltney, C. J., Swift, R. M., & Monti, P. M. (2009). A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. *Experimental and Clinical Psychopharmacology*, *17*, 122-9.

27. **Ray, L.A.**, Hutchison, K.E., Leventhal, A., Miranda, R. Jr., Francione, C., Young, D., Chelminski, I., & Zimmerman, M. (2009). Diagnosing alcohol abuse in alcohol dependent individuals: diagnostic and clinical implications. Addictive Behaviors, *34*, 587-92.
28. Magill, M., & **Ray, L.A.** (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis. Journal of Studies on Alcohol and Drugs, *70*, 516-27.
29. **Ray, L.A.**, & Hutchison, K.E. (2009). Associations among GABRG1, level of response to alcohol, and drinking behaviors. Alcoholism Clinical and Experimental Research, *33*(8), 1382-90.
30. Leggio, L., **Ray, L.A.**, Kenna, G., and Swift, R.M. (2009). Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. Alcoholism Clinical and Experimental Research, *33*(9), 1539-44
31. Leventhal, A.M., Waters, A.J., Kahler, C.W., **Ray, L.A.**, & Sussman, S. (2009). Relations between anhedonia and smoking motivation. Nicotine & Tobacco Research, *11*(9), 1047-54.
32. Witkiewitz, K., Holmes, A., **Ray, L.A.**, Murphy, J.G., Richardson, H.N., Chen, Y.-C., McDevitt-Murphy, M.E., Cruz, M.T., & Roberto, M. (2009). Young investigator award symposium. Alcohol, *43*, 499-508.
33. Miranda, R., **Ray, L.A.**, Justus, A., Meyerson, L.A., Knopik, V.S., McGeary, J., & Monti, P.M. (2010). Influence of the OPRM1 gene on adolescent alcohol misuse: mechanisms and moderators. Alcoholism Clinical and Experimental Research, *34*(1), 1-11.
34. **Ray, L.A.**, MacKillop, J., Leventhal, A., & Hutchison, K.E. (2009) Catching the alcohol buzz: an examination of the latent factor structure of subjective intoxication. Alcoholism Clinical and Experimental Research, *33*(12), 2154-2161.
35. **Ray, L.A.**, & Oslin, D.W. (2009). Naltrexone for the treatment of alcohol dependence among African Americans: Results from the COMBINE Study. Drug and Alcohol Dependence, *105*(3), 256-258.
36. **Ray, L.A.**, Capone, C., Sheets, E., Young, D., Chelminski, I., & Zimmerman, M. (2009). Posttraumatic stress disorder with and without alcohol use disorders: diagnostic and clinical correlates in a psychiatric sample. Psychiatry Research, *170* (2-3), 278-281.
37. MacKillop, J., Miranda, R., Jr., Monti, P. M., **Ray, L. A.**, Murphy, J.G., Rohsenow, D. J., McGeary, J. E., Swift, R. M., Tidey, J. W., & Gwaltney, C. J. (2010) Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. Journal of Abnormal Psychology, *119* (1), 106-114.
38. **Ray, L.A.**, Miranda Jr., R., Tidey, J.W., McGeary, J.E., MacKillop, J., Gwaltney, C.J., Rohsenow, D.J., Swift, R.M., & Monti, P.M. (2010). Polymorphisms of the μ -opioid receptor and dopamine D₄ receptor genes and subjective responses to alcohol in the natural environment. Journal of Abnormal Psychology, *119*(1), 115-125.
39. **Ray, L.A.**, Chin, P.F., & Miotto, K. (2010). Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS & Neurological Disorders – Drug Targets, *9*(1), 13-22.
40. **Ray, L.A.**, MacKillop, J., & Monti, P. (2010). Subjective responses to alcohol consumption as endophenotypes: advancing genetics into etiological and treatment models of alcoholism. Subst Use Misuse, *45*(11), 1742-1765.
41. **Ray, L.A.**, Hutchison, K.E., & Tartter, M. (2010). Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharm Des, *16*(19), 2149-2158.
42. **Ray, L.A.**, Heydari, A., & Zorick, T. (2010). Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug and Alcohol Review, *29*(5), 568-575.
43. MacKillop, J., O'Hagen, S., Lisan, S.A., Murphy, J.G., **Ray, L.A.**, McGeary, J.E., Tidey, J.W., & Monti, P.E. (2010). Behavioral economic analysis of cue-elicited craving for alcohol. Addiction, *105*(9), 1599-607.
44. **Ray, L.A.**, Hutchison, K.E., Ashenhurst, J., & Morrow, A.L. (2010). Naltrexone selectively elevates GABAergic neurosteroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. Alcoholism Clinical and Experimental Research, *34*(8), 1479-1487.

45. **Ray, L.A.**, Krull, J.L., Leggio, L. (2010). The effects of naltrexone among alcohol non-abstainers: Results from the COMBINE Study. Frontiers in Psychiatry, *10*:3389.
46. Leventhal, A., Brightman, M., Ameringer, K.J., Greenberg, J., Mickens, L., **Ray, L.A.**, & Sussman, S. (2010). Anhedonia associated with stimulant use and dependence in a population-based sample of American adults. Experimental and Clinical Psychopharmacology, *18*(6), 562-569.
47. **Ray, L.A.** (2011). Stress-induced and cue-induced craving for alcohol in heavy drinkers: Preliminary evidence of genetic moderation by the OPRM1 and CRH-BP Genes. Alcoholism Clinical and Experimental Research, *35*(1), 166-174.
48. **Ray, L.A.**, Hart, E., Chin, P.F. (2011). Self-rating of the effects of alcohol (SRE): Predictive utility and reliability across interview and self-report administrations. Addictive Behaviors, *36*(3), 241-3.
49. **Ray, L.A.** Primack, J., Young, D., Chelminski, I., & Zimmerman, M. (2011). Treatment seeking men with and without substance use disorders. Psychology of Men and Masculinity, *12*(2), 158-165.
50. **Ray, L.A.**, Hart, E., Chelminski, I., Young, D., & Zimmerman, M. (2011). Clinical correlates of desire for treatment for current alcohol dependence in patients with a primary psychiatric disorder. American Journal of Drug and Alcohol Abuse, *37*(2), 105-110.
51. Ferriter, C. & **Ray, L.A.** (2011). Binge eating and binge drinking: an integrative review. Eating Behaviors, *12*(2), 99-107.
52. MacKillop, J., Amlung, M. T., Few, L.R., **Ray, L.A.**, Sweet, L.H., Munafo, M.R. (2011). Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology, *216*(3), 305-21.
53. **Ray, L.A.**, Chin, P.F., Heydari, A., & Miotto, K. (2011). A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology, *317*(3), 341-351.
54. Tartter, M. & **Ray, L.A.** (2011). The serotonin transporter polymorphism (5-HTTLPR) and alcohol problems in heavy drinkers: moderation by depressive symptoms. Frontiers in Psychiatry, *2*:49.
55. Ashenhurst, J., Jentsch, J.D., & **Ray, L.A.** (2011). Risk-taking and alcohol use disorders symptomatology in a clinical sample. Experimental and Clinical Psychopharmacology, *19*(5):361-70.
56. Heinzerling, K.G., McCracken, J.T., Swanson, A.N., **Ray, L.A.**, Shoptaw, S.J. (2012). COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and Methamphetamine Dependence Treatment Response: Preliminary Investigation. Journal of Clinical Psychopharmacology, *32*(1):135-137.
57. Moallem, N. & **Ray, L.A.** (2012). The effects of quetiapine on response inhibition in alcohol dependent patients: a placebo-controlled pilot study. Pharmacology, Biochemistry, and Behavior, *100*(3):490-493.
58. **Ray, L.A.**, Courtney, K.E., Bujarski, S., & Squeglia, L.M. (2012). Pharmacogenetics of alcoholism: a clinical neuroscience perspective. Pharmacogenomics, *13*(2):129-132.
59. **Ray, L.A.**, Bujarski, S., Chin, P.F., & Miotto, K. (2012). Pharmacogenetics of naltrexone in Asian Americans: A randomized placebo-controlled laboratory study. Neuropsychopharmacology, *37*(2):445-455.
60. **Ray, L. A.**, Barr, C.S., Blendy, J.A., Oslin, D., Goldman, D., & Anton, R.F. (2012). The role of the Asn40Asp polymorphism of the mu opioid receptor (OPRM1) gene on alcoholism etiology and treatment: a critical review. Alcoholism Clinical and Experimental Research, *36*(3):385-394.
61. Courtney, K.E., Arellano, R., Barkley-Levenson, E., Gálvan, A., Poldrack, R.A., MacKillop, J., Jentsch, J.D., & **Ray, L.A.** (2012). The relationship between measures of impulsivity and alcohol misuse: an integrative structural equation modeling approach. Alcoholism Clinical and Experimental Research, *36*(6): 923-31.
62. Leventhal, A.M., **Ray, L.A.**, Rhee, S.H., & Unger, J.B. (2012). Genetic and environmental influences on the association between depressive symptom dimensions and smoking initiation among Chinese adolescent twins. Nicotine & Tobacco Research, *14*(5): 559-68.
63. MacKillop, J., Amlung, M., Wier, L., David, S., **Ray, L.A.**, Bickell, W., & Sweet, L.H. (2012). The neuroeconomics of nicotine dependence: an fMRI study of delay discounting of monetary and cigarette rewards in smokers. Psychiatry Research, *202*(1): 20-29.
64. Plebani, J., **Ray, L.A.**, Morean, M.E., Corbin, W.R., MacKillop, J., Amlung, M., King, A.C. (2012). Laboratory paradigms in alcohol research: a critical review. Alcoholism Clinical and Experimental Research, *36*(6):972-83

65. Bujarski, S., MacKillop, J., & **Ray, L.A.** (2012). Understanding naltrexone mechanism of action and pharmacogenetics via behavioral economics: a preliminary study. Experimental and Clinical Psychopharmacology, *20*(3): 181-190.
66. Moallem, N. & **Ray, L.A.** (2012). Dimensions of impulsivity among heavy drinkers, smokers, and heavy drinking smokers: singular and combined effects. Addictive Behaviors, *37*(7): 871-874.
67. Tartter, M. & **Ray, L.A.** (2012). A prospective study of laboratory-based stress and alcohol craving in heavy drinkers. Pharmacology, Biochemistry, and Behavior, *101*(4): 625-631.
68. **Ray, L. A.** (2012). Clinical neuroscience of addiction: Applications to psychological science and practice. Clinical Psychology: Science and Practice, *19*(2), 154-166.
69. Ashenhurst, J.R., Bujarski, S., & **Ray, L.A.** (2012). Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacology, Biochemistry, and Behavior, *103*(2), 253-259.
70. Bholat, M.A., **Ray, L.A.**, Brensilver, M., Ling, K., & Shoptaw, S. (2012). Integration of behavioral medicine in primary care. Primary Care, *39*(4), 605-614.
71. Miranda, R. Jr., Reynolds, E., **Ray, L.A.**, Justus, A., Knopik, V.S., McGeary, J., & Meyerson, L.A. (2013). Preliminary evidence for a gene-environment interaction in predicting alcohol use disorders in adolescents. Alcoholism: Clinical and Experimental Research, *37*(2), 325-331
72. **Ray, L.A.**, Bujarski, S., MacKillop, J., Courtney, K.E., Monti, P.M., & Miotto, K. (2013). Sensitivity to alcohol among alcohol dependent individuals: the effects of the mu opioid receptor (OPRM1) gene and alcoholism severity. Alcoholism: Clinical and Experimental Research, *37*(1), E116-E124
73. Bujarski, S., O'Malley, S., Lunny, K.N., & **Ray, L.A.** (2013). The effects of drinking goal on treatment outcome for alcoholism. Journal of Consulting and Clinical Psychology, *(81)*1, 13-22
74. Courtney, K.E., Ghahremani, D., & **Ray, L.A.** (2013). Fronto-striatal functional connectivity during response inhibition in alcohol dependence. Addiction Biology, *(18)*3, 593-604
75. **Ray, L.A.**, Lunny, K., Bujarski, S., Moallem, N., Krull, J.L., & Miotto, K. (2013). The effects of varenicline on stress-induced and cue-induced craving for cigarettes. Drug and Alcohol Dependence, *131*(1-2), 136-142.
76. Courtney, K.E., Ashenhurst, J., Bacio, G., Moallem, N., Bujarski, S., Hartwell, E., & **Ray, L.A.** (2013). Subjective response to alcohol and alcohol craving: Validation of the Desires for Alcohol Questionnaire (DAQ) in the human lab. Journal of Studies on Alcohol and Drugs, *74*(5), 797-802.
77. **Ray, L.A.**, Sehl, M., Bujarski, S., Hutchison, K.E., Blaine, S., & Enoch, M. (2013). The CRHR1 gene, trauma exposure, and alcoholism risk: A test of G × E effects. Genes, Brain & Behavior, *12*(4), 361-9.
78. Hartwell, E. & **Ray, L.A.** (2013). Sex moderates stress reactivity in heavy drinkers. Addictive Behaviors, *38*(11), 2643-6.
79. Moallem, N.R., Courtney, K.E., Bacio, G.A., & **Ray, L.A.** (2013). Modeling alcoholism severity: An integrative structural equation modeling approach. Frontiers in Psychiatry, *4*:75.
80. Lin, J.C., Karno, M.P., Grella, C.E., **Ray, L.A.**, Liao, D.H., & Moore, A.A. (2013) Psychiatric correlates of alcohol and tobacco use disorders in U.S. adults aged 65 and older: Results from the 2001-2002 National Epidemiologic Survey of Alcohol and Related Conditions. American Journal of Geriatric Psychiatry, S1064-7481(13)00308-4.
81. **Ray, L.A.**, Courtney, K., Hutchison, K.E., MacKillop, J., Galvan, A., & Ghahremani, D. (2013). Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues. Alcoholism: Clinical and Experimental Research, *37* Suppl 1, E116-24.
82. Miranda Jr., R., **Ray, L.A.**, Blanchard, A., Reynolds, E.K., Monti, P.M., Chun, T., Justus, A., Swift, R. M., Tidey, J., Gwaltney, C.J., & Ramirez, J. (2014). Effects of naltrexone on adolescent alcohol cue-reactivity and sensitivity: An initial randomized trial. Addiction Biology, *19*(5), 941-954.
83. Courtney, K. & **Ray, L.A.** (2014). Subjective response to alcohol in the lab predicts neural response to alcohol cues. Journal of Studies on Alcohol and Drugs, *75*(1), 124-35.
84. Bacio, G.A., Lunny, K.F., Webb, J.N., & **Ray, L.A.** (2014). Alcohol use following and alcohol challenge and a brief intervention among alcohol-dependent individuals. American Journal on Addiction, *23*(1), 96-101.

85. Bacio, G.A., Moore, A., Karno, M., & **Ray, L.A.** (2014). Determinants of problem drinking and depression among Latino day laborers. Substance Use & Misuse, 49(8), 1039-1048.
86. Miranda Jr., R., Monti, P.M., **Ray, L.A.**, Treloar, H.R., Reynolds, E.K., Ramirez, J., Chun, T., Gwaltney, C.J., Justus, A., Tidey, J., Blanchard, A., & Magill, M. (2014). Characterizing subjective responses to alcohol among adolescent problem drinkers. Journal of Abnormal Psychology, 123(1), 117-29.
87. **Ray, L.A.**, Bujarski, S., Squeglia, L.M., Ashenhurst, J.R., & Anton, R. (2014). Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. Alcohol & Alcoholism, 49(3), 261-270.
88. DeMartini, K.S., Devine, E., DiClemente, C., Martin, D., **Ray, L.A.**, & O'Malley, S.S. (2014). Predictors of pre-treatment commitment to abstinence: Results from the COMBINE Trial. Journal of Studies on Alcohol and Drugs, 75(3), 438-446.
89. MacKillop, J., Amlung, M.T., Acker, J., Gray, J.C., Brown, C.L., Murphy, J.G., **Ray, L.A.**, & Sweet, L.H. (2014). The neuroeconomics of alcohol demand: an initial investigation of the neural correlates of alcohol cost-benefit decision making in heavy drinking men. Neuropsychopharmacology, 39(8), 1988-1995.
90. Roche, D., Bujarski, S., Moallem, N., Guzman, I., Shapiro, J., & **Ray, L.A.** (2014). Predictors of smoking lapse in a human laboratory paradigm. Psychopharmacology, 231(14), 2889-2897.
91. Courtney, K., Ghahremani, D., London, E.D., & **Ray, L.A.** (2014). The association between cue reactivity in the precuneus and level of dependence on nicotine and alcohol. Drug and Alcohol Dependence, 141, 21-26.
92. Bujarski, S. & **Ray, L.A.** (2014). Subjective response to alcohol and associated craving in heavy drinkers vs. alcohol dependents: An examination of Koob's allostatic model in humans. Drug and Alcohol Dependence, 140, 161-167.
93. Ashenhurst, J.R., Bujarski, S., Jentsch, J.D., & **Ray, L.A.** (2014). Modeling behavioral reactivity to losses and rewards on the Balloon Analogue Risk Task (BART): Moderation by alcohol problem severity. Experimental and Clinical Psychopharmacology, 22(4), 298-306
94. **Ray, L.A.**, Courtney, K., Ghahremani, D., Miotto, K., Brody, A., & London, E.D. (2014). Varenicline, low dose naltrexone, and their combination for heavy drinking smokers: Human laboratory findings. Psychopharmacology, 231(19), 3843-53
95. **Ray, L.A.**, Roche, D., Heinzerling, K., & Shoptaw, S. (2014). Opportunities for the development of neuroimmune therapies in addiction. International Review of Neurobiology, 118, 381-401.
96. Sujan, A. C., Humphreys, K. L., **Ray, L. A.**, & Lee, S. S. (2014). Differential association of child abuse with self-reported versus laboratory-based impulsivity and risk-taking in young adulthood. Child Maltreatment, 19(3-4), 145-155.
97. Bacio, G.A., Guzman, I.Y., Shapiro, J.R., & **Ray, L.A.** (2014). Differences in quit attempts between Black and White daily smokers: the role of smoking motives. Addictive Behaviors, 39(12), 1769-1772.
98. Bujarski, S., Roche, D., Lunny, K., Moallem, N.R., Courtney, K.E., Allen, V., Hartwell, E., Leventhal, A., Rohrbaugh, T., & **Ray, L.A.** (2014). The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users. Drug and Alcohol Dependence, 142, 127-132.
99. Courtney, K.E. & **Ray, L.A.** (2014). Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug and Alcohol Dependence, 143, 11-21.
100. Bujarski, S. & **Ray, L.A.** (2014). Psychological distress is associated with alcohol, but not cigarette use in heavy drinking smokers. Addictive Behaviors, 39(12), 1723-1729.
101. Owens, M., **Ray, L.A.**, & MacKillop, J. (2015). Behavioral economic analysis of stress effects on acute motivation for alcohol. Journal of the Experimental Analysis of Behavior, 103(1), 77-86.
102. Bujarski, S., Roche, D.J.O., Sheets, E.S., Krull, J.L., Guzman, I., & **Ray, L.A.** (2015). Modeling naturalistic craving, withdrawal, and affect during early nicotine abstinence: a pilot EMA study. Experimental and Clinical Psychopharmacology, 23(2), 81-89.
103. Sheets, E. S., Bujarski, S., Leventhal, A. M., & **Ray, L. A.** (2015). Emotion differentiation and intensity during acute tobacco abstinence: A comparison of heavy and light smokers. Addictive Behaviors, 47, 70-73.

104. **Ray, L.A.**, Courtney, K., Ghahremani, D., Miotto, K., Brody, A. & London, E.D. (2015). Varenicline, naltrexone, and their combination for heavy drinking smokers: Preliminary neuroimaging findings. American Journal of Drug and Alcohol Abuse, *41*(1), 35-44.
105. Roche D.J.O., **Ray L.A.** (2015). Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. Pharmacogenomics, *16*(7), 721-36.
106. Roche, D.J.O., Bujarski, S., Hartwell, E., Green, R., & **Ray, L.A.** (2015). Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. Pharmacology, Biochemistry, and Behavior, *134*, 92-98.
107. **Ray, L.A.**, Bujarski, S.E., Courtney, K.E., Moallem, N.R., Lunny, K., Roche, D.J.O., Leventhal, A., Shoptaw, S., Heinzerling, K., London, E.D., & Miotto, K. (2015). The effects of naltrexone on subjective response to methamphetamine in a clinical sample: A double-blind, placebo-controlled, laboratory study. Neuropsychopharmacology, 1-10.
108. Allen, V., Myers, H.F., & **Ray, L.A.** (2015). The association between alcohol consumption and condom use: Considering correlates of HIV risk among Black men who have sex with men. AIDS & Behavior, *19*(9), 1689-1700.
109. Bujarski, S., Hutchison, K.E., Roche, D.J.O., & **Ray, L.A.** (2015). Factor structure of subjective responses to alcohol in light and heavy drinkers. Alcoholism: Clinical and Experimental Research, *39*(7), 1193-1202.
110. Bidwell, L.C., Knopik, V.S., Audrain-McGovern, J., Glynn, T.R., Spillane, N.S., **Ray, L.A.**, Riggs, N.R., Guillot, C., Pang, R.D., & Leventhal, A.M. (2015). Novelty seeking as a phenotypic marker of adolescent substance use. Substance Abuse: Research and Treatment, *9*(Suppl 1), 1-10.
111. Courtney, K.E., Ghahremani, D.G., & **Ray, L.A.** (2015). The effect of alcohol priming on neural markers of alcohol cue-reactivity. American Journal of Drug and Alcohol Abuse, *41*(4), 300-308.
112. Bujarski, S.E., Lau, A., Lee, S., & **Ray, L.A.** (2015). Genetic and environmental predictors of alcohol use in Asian American young adults. Journal of Studies on Alcohol and Drugs, *76*(5), 690-699.
113. Yardley, M.M., Mirbaba, M.M., & **Ray, L.A.** (2015). Pharmacological options for smoking cessation in heavy-drinking smokers. CNS Drugs, *29*(10), 833-845.
114. Hartwell, E.E., Bujarski, S., Glasner-Edwards, S., & **Ray, L.A.** (2015). The association of alcoholism severity with sleep quality in problem alcohol users. Alcohol & Alcoholism, *50*(5), 536-541.
115. Courtney, K.E., Schacht, J.P., Hutchison, K.E., Roche, D.J.O., & **Ray, L.A.** (2016). Neural substrates of cue-reactivity: Association with treatment outcome and relapse. Addiction Biology, *21*(1), 3-22.
116. **Ray, L.A.**, Bujarski, S., & Roche, D.J.O. (2016). Subjective response to alcohol as a research domain criterion. Alcoholism: Clinical and Experimental Research, *40*(1), 6-17.
117. Moore, A.A., Karno, M.P., **Ray, L.A.**, Ramirez, K., Barenstein, V., Portillo, M., Rizo, P., Borok, J., Liao, D.H., Barron, J., Del Pino, H.E., Valenzuela, A., Barry, K.L. (2016). Development and preliminary testing of a promotora-delivered, Spanish language, counseling intervention for unhealthy drinking among male, Latino day laborers. Journal of Substance Abuse Treatment, *62*, 96-101.
118. Inagaki, T.K., **Ray, L.A.**, Irwin, M.R., Way, B.M., Eisenberger, N.I. (2016). Opioids and social bonding: Naltrexone reduces feelings of social connection. Social Cognitive and Affective Neuroscience, *11*(5), 728-735.
119. Squeglia, L. M., Brammer, W. A., **Ray, L. A.**, & Lee, S. S. (2016). Attention-deficit/hyperactivity disorder (ADHD) symptoms predict alcohol expectancy development. Journal of Child and Adolescent Substance Abuse, *25*(2), 159-179.
120. Courtney, K.E., & **Ray, L.A.** (2016). Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development. Progress in Brain Research, *223*, 295-310.
121. Bacio, G.A. & **Ray, L.A.** (2016). Patterns of drinking initiation among Latino youths: Cognitive and contextual explanations of the immigrant paradox. Journal of Child & Adolescent Substance Abuse, 1-11.
122. Roche, D.J.O., **Ray, L.A.**, Yardley, M.M., & King, A.C. (2016). Current insights into the mechanisms and treatments for heavy-drinking cigarette smokers. Current Addiction Reports, *3*(1), 125-137.

123. Roche, D.J.O., Lunny, K.F., Yardley, M.M., Louie, S.G., Davies, D.L., Miotto K., & **Ray L.A.** (2016). A Pilot study of the safety and initial efficacy of ivermectin for the treatment of alcohol use disorder. *Alcoholism: Clinical and Experimental Research*, *40*(6), 1312-1320.
124. Green, R., Bujarski, S., Roche, D.J.O., & **Ray, L.A.** (2016). Relationship between negative affect and smoking topography in heavy drinking smokers. *Addictive Behaviors*, *61*, 53-57.
125. Chung, T., Noronha, A., Carroll, K.M., Potenza, M.N., Hutchison, K., Calhoun, V.D., Gabrieli, J.D.E., Morgenstern, J., Nixon, S.J., Wexler, B.E., Brewer, J., **Ray, L.A.**, Filbey, F., Strauman, T.J., Kober, H., & Feldstein Ewing, S.W. (2016). Brain Mechanisms of Change in Addiction Treatment: Models, Methods, and Emerging Findings. *Current Addiction Reports*, *3*(3), 332-342.
126. Bujarski, S. & **Ray, L.A.** (2016). Experimental psychopathology paradigms for alcohol use disorder: Applications for translational research. *Behaviour Research and Therapy*, *86*, 11-22.
127. Courtney, K.E., Ghahremani, D.G., & **Ray, L.A.** (2016). The effects of pharmacological opioid blockade on neural measures of drug cue-reactivity in humans. *Neuropsychopharmacology*, *41*(12), 2872-2881.
128. Hartwell, E.E., Moallem, N.R., Courtney, K.E., Glasner-Edwards, S., & **Ray, L.A.** (2016). Sex differences in the association between internalizing symptoms and craving in methamphetamine users. *Journal of Addiction Medicine*, *10*(6), 395-401.
129. Cservenka, A. & **Ray, L.A.** (2017). Self-reported attentional and motor impulsivity are related to age at first methamphetamine use. *Addictive Behaviors*, *65*, 7-12.
130. Hartwell, E.E., & **Ray, L.A.** (2017). Craving as a DSM-5 symptom of alcohol use disorder in non-treatment seekers. *Alcohol & Alcoholism*, *14*, 1-6.
131. Bujarski, S.E., Hutchison, K.E., Prause, N., & **Ray, L.A.** (2017). Functional significance of subjective response to alcohol across levels of alcohol exposure. *Addiction Biology*, *22*(1), 235-245.
132. Cummings, J.R., **Ray, L.A.**, & Tomiyama, A.J. (2017). Food-alcohol competition: As young females eat more food, do they drink less alcohol? *Journal of Health Psychology*, *22*(5), 674-683.
133. Yardley, M., & **Ray, L.A.** (2017). Medications development for the treatment of alcohol use disorder: Insights into the predictive value of animal paradigms and human laboratory models. *Addiction Biology*, *22*(3), 581-615.
134. Bello, M.S., Pang, R.D., Chasson, G.S., **Ray, L.A.**, & Leventhal, A.M. (2017). Obsessive-Compulsive Symptoms and Negative Affect During Tobacco Withdrawal in a Non-Clinical Sample of African American Smokers. *Journal of Anxiety Disorders*, *48*, 78-86.
135. Cservenka, A., Yardley, M.M., & **Ray, L.A.** (2017). Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. *The American Journal on Addictions*, *26*(5), 516-525.
136. Bullock, K., Cservenka, A., & **Ray, L.A.** (2017). Severity of alcohol dependence is negatively related to hypothalamic and prefrontal cortical gray matter density in heavy drinking smokers. *American Journal of Drug and Alcohol Abuse*, *43*(3), 281-290.
137. Westman, J., Bujarski, S.E., & **Ray, L.A.** (2017). Impulsivity moderates subjective responses to alcohol in alcohol dependent individuals. *Alcohol & Alcoholism*, *52*(2), 249-255.
138. Lim, A., Cservenka, A., & **Ray, L.A.** (2017). Effects of alcohol dependence severity on neural correlates of delay discounting. *Alcohol & Alcoholism*, *52*(4), 506-515.
139. **Ray, L.A.**, Bujarski, S.E., Shoptaw, S., Roche, D.J.O., Heinzerling, K., & Miotto, K. (2017). Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: A randomized, placebo-controlled, human laboratory trial. *Neuropsychopharmacology*, *42*, 1776-1788.
140. **Ray, L.A.**, Bujarski, S., Yardley, M.M., Roche, D.J.O., & Hartwell, E. (2017). Differences between treatment-seeking and non-treatment seeking participants in medication studies for alcoholism: Do they matter? *American Journal of Drug and Alcohol Abuse*, *43*, 703-710.
141. Roche, D.J.O., Worley, M., Courtney, K., Bujarski, S., London, E., Shoptaw, S., **Ray, L.A.** (2017). Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. *Psychopharmacology*, *234*(13), 1997-2007.

142. Cservenka, A., Courtney, K., Ghahremani, D., Hutchison, K.E., & **Ray, L.A.** (2017). Development, initial testing, and challenges of an ecologically valid reward prediction error fMRI task for alcoholism. *Alcohol & Alcoholism*, 52(5), 617-624.
143. **Ray, L.A.**, Green, R., Roche, D.J.O., Bujarski, S.E., Hartwell, E. E., Lim, A., Rohrbaugh, T., Ghahremani, D., Hutchison, K.E., & Miotto, K. (2017). Pharmacogenetic effects of naltrexone in individuals of East Asian descent: Human laboratory findings from a randomized trial. *Alcoholism: Clinical and Experimental Research*.
144. Garneau, H. C., Venegas, A., Rawson, R., **Ray, L. A.**, & Glasner, S. (2018). Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders. *Journal of Substance Abuse Treatment*, 85, 34-37.

Peer-Reviewed Commentaries & Editorials

1. Hutchison, K.E. & **Ray, L.A.** (2011). New approaches to identifying rare genetic variants associated with nicotine dependence. *Biological Psychiatry*, 70(6), 500-1.
2. **Ray, L.A.** (2015). A matter of outlook. *Alcoholism: Clinical and Experimental Research*, 39(4), 590.
3. **Ray, L.A.** & Bujarski, S.E. (2015). Mechanisms of topiramate effects: Refining medications development for alcoholism. *Addiction Biology*, 21(1), 183-184.

Book Chapters

1. **Ray, L.A.**, Hutchison, K.E., & Hauser, M. (2008). Alcohol use disorders: history, theory, and diagnosis. In W.E. Craighead, D.J. Miklowitz, & L.C. Craighead (Eds.). *Psychopathology: History, Diagnosis, and Empirical Foundations* (pp. 495-523). John Wiley and Sons.
2. **Ray, L.A.** & Hutchison, K.E. (2009). Genetics of addiction. In L.M. Cohen, F.L. Collins, A. Young, D.E. McChargue, T.R. Leffingwell, & K.L. Cook (Eds.). *The Pharmacology and Treatment of Substance Abuse: Evidence and Outcomes Based Perspectives* (pp. 109-126). Routledge.
3. MacKillop, J., McGeary, J.E., **Ray, L.A.** (2010). Genetic influences on addiction: Alcoholism as an exemplar. In D. Ross, P. Collins, & D. Spurrett (Eds.). *What is Addiction?* (pp. 53-98). MIT Press.
4. **Ray, L.A.** & Hutchison, K.E. (2010). Molecular genetics and the treatment of addiction. In B. Johnson (Ed.). *Addiction Medicine: Science and Practice, First Edition* (pp. 1101-1114). Springer.
5. MacKillop, J., Amlung, M.T., Murphy, C.M., Acker, J. & **Ray, L.A.** (2011). A Behavioral Economic Approach to Health Behavior. In: R. DiClemente, L.F. Salazar, and R.A. Crosby (Eds.) *Health Behavior Theory for Public Health: Principles, Foundations, and Applications* (pp. 131-161). Jones and Bartlett Publishers, LLC.
6. Monti, P.M. & **Ray, L.A.** (2012). The study of craving and its role in addiction. In K. D. Brownell & M.S. Gold (Eds.). *Food and Addiction* (pp. 53-58). Oxford University Press.
7. **Ray, L. A.**, & Courtney, K. E. (2013). Addiction. In Hal Pashler (Ed.), *Encyclopedia of the Mind, (Vol. 1, pp. 8-11)*. Sage.
8. Miotto, K.M., Heydari, A., Tartter, M., Chang, E., Thomas, P.S., & **Ray, L.A.** (2013). Adolescent Alcohol Use, In R. Rosner (Ed.). *Clinical Handbook of Adolescent Addiction* (pp.179-189). Wiley-Blackwell.
9. **Ray, L.A.**, Courtney, K., Bacio, G., & MacKillop, J. (2013). Assessment of Craving in Addiction Research. In J. MacKillop and H. de Witt (Eds.). *The Wiley-Blackwell Handbook of Addiction Pharmacology* (pp. 345-380). Wiley-Blackwell.
10. **Ray, L.A.**, Courtney, K.E., & Bacio, G. (2013). Alcohol use disorders. In W.E. Craighead, D.J. Miklowitz, & L.C. Craighead (Eds.). *Psychopathology: History, Diagnosis, and Empirical Foundations, 2nd Edition* (pp. 550-582). John Wiley and Sons.
11. **Ray, L.A.** & Heilig, M. (2014). Subjective responses to alcohol: Implications to alcoholism etiology and treatment development, In J. MacKillop and M. Munafo (Eds.). *Genetic Influences on Addiction: An Intermediate Phenotype Approach* (pp. 97-120). Wiley-Blackwell.
12. **Ray, L.A.**, Courtney, K.E., Roche, D., & Miotto, K. (2015). Application of functional neuroimaging to the treatment of addiction: Focus on pharmacotherapies. In S.W. Feldstein-Ewing, K. Witkiewitz, & F.M.

Filbey (Eds.), *Neuroimaging and Psychosocial Addiction Treatment: An Integrative Guide for Researchers and Clinicians*. Palgrave.

Manuscripts Under Review or In Revision

Symposia and Paper Presentations at Scientific Meetings

1. **Ray, L. A.** & Hutchison, K.E. (2003). *Psychosocial factors associated with alcohol pathology in a college sample*. Paper presented at the annual meeting of the Society for the Advancement of Chicanos and Native Americans in Science, Albuquerque, NM.
2. Hutchison, K.E., **Ray, L.A.**, & Smolen, A. (2003). Sensitivity to alcohol in humans: Influence of the VNTR promoter polymorphism of the serotonin transporter and GABA6 C/T SNP. In K. Fromme (Chair), *Biological and behavioral markers of alcohol sensitivity*. Symposium at the annual meeting of the Research Society on Alcoholism, Fort Lauderdale, FL.
3. **Ray, L.A.**, & Hutchison, K. (2004). A polymorphism of the μ -opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. In H. Kranzler (Chair), *Human Genetics*. Paper presented at the annual meeting of the Research Society on Alcoholism, Vancouver, Canada.
4. **Ray, L.A.**, Hutchison, K.E., Marshall, E., McCarthy, S., & Hutz, C. (2005). *Alcohol use and misuse cross-culturally: A critical review*. Paper presented at the annual meeting of the International Council of Psychologists, Iguacu Falls, Brazil.
5. **Ray, L.A.**, & Hutchison, K.E. (2005). Psychosocial predictors of treatment outcome, dropout, and change processes in a clinical trial for alcohol dependence. In R. Swift (Chair), *Moderators of Treatment Outcome*. Paper presented at the annual meeting of the Research Society on Alcoholism, Santa Barbara, CA.
6. **Ray, L.A.** & Hutchison, K.E. (2007). Behavioral, laboratory, and genetic correlates of low level of response to alcohol. In K. Fromme (Chair), *Subjective responses to alcohol*. Paper presented at the meeting of the Research Society on Alcoholism, Chicago, IL.
7. Hutchison, K.E. & **Ray, L.A.** (2007). Elucidating variables that influence stimulation: Alcohol infusion versus alcohol ingestion. In A. King (Chair), *Alcohol administration studies*. Symposium presented at the annual meeting of the Research Society on Alcoholism, Chicago, IL.
8. **Ray, L.A.**, & Hutchison, K.E. (2007). Pharmacogenetics of naltrexone: Results from human laboratory studies. In D.W. Oslin (Chair), *Pharmacogenetics of Naltrexone: Meaningful Genetic Variation in the Opioid System*. Symposium presented at the annual meeting of the Research Society on Alcoholism, Chicago, IL.
9. **Ray, L.A.**, Primack, J., Chelminski, I., Young, D., & Zimmerman, M. (2008). The diagnostic and clinical profile of treatment-seeking men with and without a lifetime history of substance use disorders. In A. Marcaccio (Chair): *Moving from clinical theorizing to clinical research and practice with men*. Symposium presented at the meeting of the American Psychological Association, Boston, MA.
10. **Ray, L.A.**, Chelminski, I., Young, D., & Zimmerman, M. (2008). Diagnosing Alcohol Use Disorders: Results from a Clinical Epidemiological Sample. In L.A. Ray and A. Leventhal (Co-Chairs), *Diagnostic and Assessment Issues in Substance Use Disorders*. Symposium presented at the meeting of the American Psychological Association, Boston, MA.
11. Swift, R. & **Ray, L.A.** (2008). Stress, opioid systems and naltrexone response. In G.F. Koob and M. Roberto (Chairs). *Costicosteroids and Therapeutic Targets in Alcohol Dependence*. Symposium presented at the international conference on Alcoholism and Stress: A Framework for Future Treatment Strategies, Volterra, Pisa, Italy.
12. **Ray, L.A.**, Hutchison, K.E., & Monti, P.M. (2008). Naltrexone, genes, and behavior: Examining the role of stress and HPA-axis activation. In G.F. Koob and M. Roberto (Chairs). *Costicosteroids and Therapeutic Targets in Alcohol Dependence*. Symposium presented at the international conference on Alcoholism and Stress: A Framework for Future Treatment Strategies, Volterra, Pisa, Italy.

13. **Ray, L.A.** (2008). PTSD with and without alcohol use disorders: diagnostic and clinical correlates in a psychiatric sample. In F. Crews and F. Noronha (Chairs), *Young Investigator Symposium* presented at the international conference on Alcoholism and Stress: A Framework for Future Treatment Strategies, Volterra, Pisa, Italy.
14. **Ray, L.A.** (2008). Innovative approaches to studying behavioral genetics of addiction through endophenotype-driven models. In M. Drapkin and J. McKay (Chairs), Roundtable presented at the annual meeting of the Research Society on Alcoholism, Washington, DC.
15. **Ray, L.A.** (2009). The Asn40Asp SNP of the OPRM1 gene and subjective responses to alcohol in the laboratory and in the natural environment. In C. Barr (Chair), *OPRM1 Variation and Reward Sensitivity: Translation across Species and Situation*. Symposium presented at the annual Winter Conference on Brain Research, Copper Mountain, CO.
16. **Ray, L.A.** (2009). Behavioral genetics and laboratory paradigms for alcoholism: stress and craving phenotypes. In **L. Ray** and J. Plebani (Chairs), *In with the new: Novel approaches and future directions in human laboratory studies of alcoholism*. Symposium presented at the annual meeting of the Research Society on Alcoholism, San Diego, CA.
17. Morrow, A.L., **Ray, L.A.**, & Hutchison, K.E. (2009). Naltrexone increases GABAergic neurosteroids in heavy drinkers with the mu-opioid receptor Asn40Asp polymorphism. *Breaking News Symposium*. Symposium presented at the annual meeting of the European College of Neuropsychopharmacology, Istanbul, Turkey.
18. **Ray, L.A.** (2009). The Asn40Asp SNP of the oprm1 gene and responses to alcohol in the laboratory and in the natural environment. In William Copeland (Chair), *OPRM1 Variation and Reward Seeking: Translation Across Species, Outcome, and Development*. Symposium presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI.
19. Miranda Jr., R., **Ray, L.A.**, Justus, A., Meyerson, L.A., Knopik, V.S., McGeary, J.E., & Monti, P.M. (2009). Initial evidence of an association between the OPRM1 gene and adolescent alcohol misuse: mechanisms and moderators. In William Copeland (Chair), *OPRM1 Variation and Reward Seeking: Translation Across Species, Outcome, and Development*. Symposium presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI.
20. **Ray, L.A.** (2010). OPRM1 Variation and Mechanisms of Stress, Craving, and Subjective Intoxication among Alcohol Dependent and Non-Dependent Drinkers. In **L.A. Ray** & R. Anton (Chairs), *Genetic variation in the mu-opioid receptor gene and alcoholism phenotypes: from mouse to man*. Symposium accepted for presentation at the annual meeting of the Research Society on Alcoholism, San Antonio, TX.
21. **Ray, L.A.**, Ashenhurst, J. (2010). Risky decision making in individuals with alcohol use disorders: genetic and clinical moderators. In **L.A. Ray** & D. Jentsch (Chairs), *Risky decision making and alcohol use disorders: findings at the behavioral, genetic, and neural levels of analysis*. Symposium presented at the annual meeting of the Research Society on Alcoholism, San Antonio, TX.
22. **Ray, L.A.**, Tartter, M., Hart, E., Chin, P.F., MacKillop, J., & Miotto, K. (2010). Laboratory phenotypes for alcoholism as predictors of alcohol use and treatment response. In **L.A. Ray** & A. Rose (Chairs), *Experimental laboratory models in alcohol research: Translating from the lab to the clinic*. Symposium presented at the meeting of the International Society for Biomedical Research on Alcoholism (ISBRA), Paris, France.
23. Tartter, M., & **Ray, L.A.** (2011). A prospective study of laboratory-based stress and craving in heavy drinkers. In S.S. Lee and **L.A. Ray** (Chairs), *Developmental perspectives on gene × environment interaction in psychopathology*. Symposium presented at the annual meeting of the Western Psychological Association, Los Angeles, CA.
24. **Ray, L.A.** (2011). Genetic influences on alcoholism risk: an examination of human laboratory phenotypes of stress, craving, and subjective intoxication. In M. Enoch (Chair), *Genetic origins of alcohol and nicotine dependence*. Symposium presented at the meeting of the International Behavioural and Neural Genetics Society (IBANGS), Rome, Italy.
25. **Ray, L.A.** (2011). OPRM1 variation and mechanisms of stress, craving, and subjective intoxication among alcohol dependent and non-dependent drinkers. In C. O'Brien and M. Heilig (Chairs),

- Opioid/ethanol interactions: genetic and therapeutic aspects.* Symposium presented at the annual meeting of the Research Society on Alcoholism, Atlanta, GA.
26. **Ray, L.A.**, Courtney, K., Ghahremani, D., London, E., & Miotto, K. (2012). Medications for heavy drinking smokers: Effects of varenicline, naltrexone, and their combination. In **L.A. Ray** and A. King (Chairs), *Medication development for alcohol dependence, nicotine dependence, and their co-occurrence: Translational approaches.* Symposium presented at the annual meeting of the Research Society on Alcoholism, San Francisco, CA.
 27. **Ray, L.A.**, & Lunny, K. (2012). Treating nicotine dependence: Effects of varenicline on stress- and cue-induced craving for cigarettes. In **L.A. Ray** (Chair), *Treatment development for alcohol and nicotine dependence: A translational approach.* Symposium presented at the annual meeting of the American Psychological Association, Society of Addiction Psychology (Division 50), Orlando, FL.
 28. Bujarski, S., & **Ray, L.A.** (2012). Treating alcohol dependence: Human laboratory studies of quetiapine and naltrexone. In **L.A. Ray** (Chair), *Treatment development for alcohol and nicotine dependence: A translational approach.* Symposium presented at the annual meeting of the American Psychological Association, Society of Addiction Psychology (Division 50), Orlando, FL.
 29. Courtney, K., & **Ray, L.A.** (2012). Treating heavy drinking smokers: The singular and combined effects of varenicline and naltrexone. In **L.A. Ray** (Chair), *Treatment development for alcohol and nicotine dependence: A translational approach.* Symposium presented at the annual meeting of the American Psychological Association, Society of Addiction Psychology (Division 50), Orlando, FL.
 30. **Ray, L.A.**, & Bujarski, S. (2012). Pharmacogenetics of naltrexone in individuals of East Asian descent: Results from a human laboratory trial. In G.A. Kenna & **L.A. Ray** (Chairs), *Targeting pharmacologic determinants of alcohol use via human laboratory models.* Symposium presented at the meeting of the International Society for Biomedical Research on Alcoholism (ISBRA), Sapporo, Japan.
 31. **Ray, L.A.** & Courtney, K. (2013). Clinical neuroscience of addiction. Implications for research and practice. Lecture presented at the first collaborative meeting of the APA division 28 and division 50, *Collaborative Perspectives on Addiction*, Atlanta, GA.
 32. **Ray, L.A.**, Bujarski, S., & Courtney, K. (2013). Genetics of alcoholism: A multi-method translational approach. In J. MacKillop (Chair), *Strategies for Understanding the Role of Genetics in Alcoholism and Drug Addiction.* Symposium presented at the annual meeting of the American Psychological Association, Society of Addiction Psychology (Division 50), Honolulu, HI.
 33. **Ray, L.A.** (2013). Clinical neuroscience of addiction: Implications for research and practice. Workshop presented at the annual meeting of the American Psychological Association, Society of Addiction Psychology (Division 50), Honolulu, HI.
 34. **Ray, L.A.** & Roche, D. (2013). Human laboratory models in medication development for alcoholism: In D.L Davies (Chair), *Strategies to Meet the Challenges of Drug Discovery & Drug Development for Alcohol Use Disorders.* Symposium presented at the annual meeting of the Research Society on Alcoholism, Orlando, FL.
 35. Roche, D. & **Ray, L.A.** (2013). Medications development. In R. Swift (Chair), *The Conduct of Human Laboratory Studies in Alcohol Research.* Workshop sponsored by the National Institute on Alcohol Abuse and Alcoholism, presented at the meeting of the European Society for Biomedical Research on Alcoholism (ESBRA), Warsaw, Poland.
 36. Courtney, K.E. & **Ray, L.A.** (2013). Subjective responses to alcohol in the lab predict neural responses to alcohol cues. In R. Swift (Chair), *Innovative Techniques in Human Laboratory Alcohol Research.* Symposium presented at the meeting of the European Society for Biomedical Research on Alcoholism (ESBRA), Warsaw, Poland.
 37. **Ray, L.A.** (2013). Naltrexone effects on GABAergic neuroactive steroids: associations to subjective responses and pharmacogenetics. In R. Swift (Chair), *Naltrexone Revisited: New Findings Beyond Mu, Beyond Dopamine and Beyond Addiction.* Symposium presented at the annual meeting of the American College on Neuropsychopharmacology, Hollywood, FL.
 38. **Ray, L.A.** (2014). Functional connectivity during response inhibition and alcohol cues processing in alcoholism. In J. Schacht (Chair), *Alcohol and the connectome: Functional connectivity approaches to*

understanding the development and progression of alcoholism. Symposium presented at the annual meeting of the Research Society on Alcoholism, Seattle, WA.

39. **Ray, L.A.** (2015). Human laboratory models of addiction and PTSD. In J. Morrow (Chair), *Shared neurobiology of addiction and post-traumatic stress disorder*. Symposium presented at the annual Winter Conference on Brain Research, Big Sky, MT.
40. **Ray, L.A.** & Courtney, K.E. (2015). Imaging mechanisms of change: Medication effects on functional connectivity during cue-exposure. In S. Feldstein & T. Chung (Chairs), *Neuroimaging Mechanisms of Change in Psychotherapy for Addictive Behaviors*. Satellite meeting for the Research Society on Alcoholism, San Antonio, TX.
41. **Ray, L.A.** (2015). A research agenda on the clinical neuroscience of alcoholism. Plenary session presented at the annual meeting of the Research Society on Alcoholism, San Antonio, TX.

Invited Lectures

1. *Preliminary results from the alcohol infusion study*. General Clinical Research Center, University of Colorado at Boulder. (2004).
2. *The μ -opioid receptor gene (OPRM1) and alcohol sensitivity among heavy drinkers*. Institute for Behavioral Genetics, University of Colorado at Boulder. (2004).
3. *The empirical support for Dialectical Behavior Therapy (DBT) as a treatment for substance use disorders*. Addiction Recovery Center, Division of Public Health. Boulder, CO. (2005).
4. *Examining the heritability of craving for cigarettes and tension reduction after cigarette smoking: Results from an experimental twin study*. Institute for Behavioral Genetics, University of Colorado at Boulder. (2006).
5. *Pharmacogenetics of naltrexone: from endophenotypes to the clinical treatment of alcohol use disorders*. Alcohol Research Center, University of Connecticut Health Science Center, Farmington, CT. (2007).
6. *Pharmacogenetics of naltrexone: from endophenotypes to the clinical treatment of alcohol use disorders*. Brown University Center for Alcohol and Addiction Studies, Providence, RI. (2007).
7. *Pharmacogenetics of naltrexone*. Center for Studies of Addiction. University of Pennsylvania Medical School, Philadelphia, PA. (2007).
8. *Pharmacogenetics of naltrexone: from endophenotypes to the clinical treatment of alcohol use disorders*. Department of Psychology, Northwestern University, Evanston, IL. (2007).
9. *Diagnosing alcohol use disorders: moving towards DSM-V*. Department of Psychology, Northwestern University, Evanston, IL. (2007).
10. *Pharmacogenetics of naltrexone: from endophenotypes to the clinical treatment of alcohol use disorders*. Department of Psychology, University of Pennsylvania, Philadelphia, PA. (2007).
11. *Diagnosing alcohol use disorders: moving towards DSM-V*. Department of Psychology, University of Pennsylvania, Philadelphia, PA. (2007).
12. *Pharmacogenetics of naltrexone: from endophenotypes to the clinical treatment of alcohol use disorders*. Department of Psychology, University of California, Los Angeles, CA. (2007).
13. *Diagnosing alcohol use disorders: moving towards DSM-V*. Department of Psychology, University of California, Los Angeles, CA. (2007).
14. *Translational research in alcohol use disorders*. Health Psychology Seminar Series. UCLA, Department of Psychology, Los Angeles, CA. (2008).
15. *Translational research in alcohol use disorders*. Clinical Psychology Brown Bag Series. UCLA, Department of Psychology, Los Angeles, CA. (2008).
16. *Molecular genetics of alcoholism etiology and treatment*. Lecture at the Neurogenetics Affinity Group. UCLA. (2009).
17. *Treating alcohol use disorders*. Core lecture for medical residents in psychiatry (PGY-3). UCLA, Department of Psychiatry and Biobehavioral Sciences. (2009).
18. *Motivational interviewing with substance abusers*. Core lecture for medical residents in psychiatry (PGY-3). UCLA, Department of Psychiatry and Biobehavioral Sciences. (2010).

19. *Experimental and clinical psychopharmacology of addiction*. Health Promotion Seminar Series. University of Southern California, Department of Preventive Medicine in the USC Keck School of Medicine, Los Angeles, CA. (2010).
20. *Clinical research and practice in alcoholism*. Core lecture for medical residents in psychiatry (PGY-3). UCLA, Department of Psychiatry and Biobehavioral Sciences. (2011).
21. *Clinical neuroscience of addiction*. Neuroscience Seminar Series. California State University, Los Angeles, Department of Psychology, Los Angeles, CA. (2011).
22. *Psychology and primary care*. Health Psychology Seminar Series. UCLA, Department of Psychology, Los Angeles, CA. (2011).
23. *Experimental and clinical psychopharmacology of addiction*. Learning & Behavior Seminar Series. UCLA, Department of Psychology, Los Angeles, CA. (2011).
24. *Clinical neuroscience of addiction*. Addiction Psychiatry Seminar Series. UCLA Department of Psychiatry and Biobehavioral Science, Brain Research Institute, Los Angeles, CA. (2011).
25. *Subjective intoxication: an intermediate phenotype for alcoholism*. Second Annual Symposium of the Center for Contextual Genetics and Prevention Science. University of Georgia, Athens, GA. (2011).
26. *Clinical neuroscience of addiction*. Integrated Substance Abuse Programs (ISAP). UCLA, Los Angeles, CA. (2011).
27. *Alcoholism treatment: current evidence and future targets*. Alcohol Across the Lifespan: What Physicians Need to Know. Università La Sapienza, Roma and National Institute on Alcohol Abuse and Alcoholism, Rome, Italy. (2011).
28. *Career in a doctoral research university-extensive*. Panelist in Academic Career Paths in Clinical Psychology. American Psychological Association, Division 12. Washington, DC. (2011).
29. *Pharmacotherapy for alcoholism: clinical findings, mechanisms of action, and pharmacogenetics*. Invited plenary section at the Addiction medicine: State of the Art 2011 meeting of the California Society of Addiction Medicine, Long Beach, CA. (2011).
30. *Clinical neuroscience of alcoholism*. Invited lecture at the Stefan and Shirley Hatos Center for Neuropharmacology, UCLA Brain Research Institute, Los Angeles, CA. (2012).
31. *Clinical neuroscience of alcoholism*. Invited lecture at the Treatment Research Center, University of Pennsylvania School of Medicine, Department of Psychiatry, Philadelphia, PA. (2012).
32. *Genetics of alcoholism: A translational and experimental approach*. Invited lecture at the Polish and U.S. collaborative meeting. National Institute on Alcohol Abuse and Alcoholism, San Francisco, CA. (2012).
33. *Clinical neuroscience of alcoholism*. Keynote address at the Center in Review and Fellowship Graduation, Brown University Center for Alcohol and Addiction Studies, Providence, RI. (2012).
34. *Treatment development for heavy drinking smokers*. Invited lecture at the Minority Institute on Drug Abuse Research Program, 7th Substance Abuse Research Symposium. Charles Drew University of Medicine and Science, Los Angeles, CA. (2012).
35. *Behavioral pharmacology of addiction: A clinical approach*. Invited lecture Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, Baltimore, MD. (2012).
36. *Clinical neuroscience of addiction: Focus on nicotine dependence*. Invited lecture, Department of Public Health, University of Texas Southwestern School of Health Professions, Dallas, TX. (2012).
37. *College student drinking*. Invited lecture, UCLA Counseling and Psychological Services, Los Angeles, CA. (2013).
38. *Clinical neuroscience of addiction*. Invited lecture at the National Institute of Drug Abuse (NIDA) Intramural Research Program, Baltimore, MD. (2014).
39. *Naltrexone and alcoholism: Basic and clinical studies*. Invited lecture at the 8th IGAKUKEN International Symposium on Pain Modulation and Opioid Functions, Tokyo, Japan. (2015).
40. *Clinical neuroscience of addiction: from etiology to treatment*. Keynote lecture at McMaster University, Department of Psychiatry Research Day, Hamilton, Canada. (2015).
41. *Naltrexone Pharmacogenetics: Why it works for some and not others?* Invited plenary for the 2015 meeting of the California Society of Addiction Medicine, San Francisco, CA. (2015).

42. *A Research Program on the Clinical Neuroscience of Addiction*. Invited lecture at the Addiction Science Division, Department of Psychiatry and Behavioral Sciences. Medical University of South Carolina, Charleston, SC. (2015).

TEACHING EXPERIENCE

Graduate Courses

Psychology 270C: Clinical Psychology Foundations, Addiction Module (taught yearly 2008-present)
 Psychology 298: Evidence-based Psychological Treatments for Adult Psychopathology (2013)
 Psychology 403: Detection and Treatment of Alcohol and Chemical Substance Dependency (2015)
 Psychology 401: Clinical Supervision, Psychotherapy Practicum (taught yearly 2008-present)
 Psychology 227: Clinical Supervision, Assessment Practicum (2010)

Undergraduate Courses

Psychology 127B: Abnormal Psychology, Biological Bases (taught bi-yearly 2008-present)
 Psychology 162: Psychology of Addiction (taught bi-yearly 2008-present)
 Psychology 189: Honors section for Psychology of Addiction (2015)
 Psychology 10: Introduction to Psychology (Clinical psychology module, 2009, 2010, and 2011)

CLINICAL EXPERIENCE

2009-present **Co-Director and Clinical Supervisor**, Behavioral Medicine and Addiction Clinic at the UCLA Family Health Center, UCLA Department of Family Medicine

July 2007-June 2008 **Postdoctoral Fellow**
 Center for Alcohol and Addiction Studies, Brown University Medical School, Providence, Rhode Island

July 2007-June 2008 **Volunteer Psychologist**
 Rhode Island Free Clinic, Providence, Rhode Island
 Responsible for providing mental health services to multicultural and economically underserved population; clinical services also provided in Spanish and Portuguese.

July 2007-June 2008 **Supervised Private Practice**
 Butler Hospital Campus, Providence, Rhode Island

Jul 2006-Jun 2007 **Clinical Psychology Intern, Adult Track**
 Brown University Medical School, Department of Psychiatry and Human Behavior, Providence, Rhode Island
Rotations: Butler Partial Hospital Program; VA Medical Center Alcohol and Drug Treatment Program; Rhode Island Hospital Sleep and Anxiety Disorders Clinic; Butler Outpatient Clinic.

PROFESSIONAL ACTIVITIES

Grant Reviewing

NIAAA, AA-3, Clinical, Treatment, and Health Services Research Subcommittee, appointed standing member, 2013-2017
 NIAAA Special Emphasis Panel, ZAA1 DD(03) , June 2011
 NIAAA, AA-2, Epidemiology, Prevention, and Behavior Research, ad hoc, March 2012
 NIAAA, Work Group for Alcohol Research Centers, ZAA1 GG (60), July 2012
 VA SPLC/Genetics CSSEC Review Panel, December 2011
 Belgium Science Policy Office, ad hoc, October 2011

Expert Panels

Member, Consensus Panel on New Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities; *Chair* of subgroup on New Pharmacotherapies for Adults. Meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA), Rockville, MD. (2012).

Presenter, Alcoholism treatment: current evidence and future targets. Alcohol Across the Lifespan: What Physicians Need to Know. Università La Sapienza, Roma and National Institute on Alcohol Abuse and Alcoholism (NIAAA), Rome, Italy. (2011).

Presenter, Poland and U.S. collaborative research meeting on alcoholism. National Institute on Alcohol Abuse and Alcoholism (NIAAA), San Francisco, CA. (2012).

Editing and Reviewing

Alcoholism: Clinical and Experimental Research, *Field Editor*

Alcohol & Alcoholism, *Associate Editor*

Clinical Psychology Science and Practice, *Associate Editor*

Frontiers in Addictive Disorders, *Associate Editor*

Psychology of Addictive Behaviors, *Review Editor*

Frontiers in Human Genetics, *Review Editor*

Ad hoc reviewer for:

Addictive Behaviors; Addiction; Addiction Biology; Alcohol & Alcoholism; Alcohol Research & Health; Alcoholism: Clinical and Experimental Research; American Journal of Medical Genetics; Neuropsychiatric Genetics; Archives of General Psychiatry; Behavior Therapy; Behavioral and Brain Functions; Biological Psychology; Clinical Psychology Review; Current Drug Abuse Reviews; Current Pharmaceutical Design; Developmental Cognitive Neuroscience; Drug and Alcohol Dependence; Drug and Alcohol Review; Genes, Brain, and Behavior; International Journal of Neuropsychopharmacology; International Journal of Psychiatry in Medicine; Journal of Clinical Psychology; Journal of Clinical Psychopharmacology; Journal of Studies on Alcohol and Drugs; Nature Reviews Neuroscience, Neuroscience Letters; Nicotine & Tobacco Research; Psychiatry Research; Psychological Science; Psychology of Addictive Behaviors; Psychopharmacology; Psychoneuroendocrinology; The Pharmacogenomics Journal

Professional Affiliations

American College of Neuropsychopharmacology (ACNP, associate member)

American Psychological Association (APA)

Society of Addiction Psychology, APA (Div. 50)

Society of Clinical Psychology, APA (Div. 12)

Research Society on Alcoholism (RSA)

Professional Committees

2016	Chair , Program Committee, APA Division 50, Society for Addiction Psychology
2013-2014	Co-Chair , Clinic and Placements Committee, UCLA Psychology Department
2013-	Elected Board Member , Research Society on Alcoholism (RSA)
2013-	Monica Salinas Scholarship Fund Committee , UCLA Psychology Department
2013-	Scientific Advisory Committee , UCLA Clinical and Translational Science Institute (CTSI)
2012-2013	Search Committee , Staglin Chair, UCLA Psychology Department
2012	Conference Program Committee , Research Society on Alcoholism (RSA)
2011-2014	Education Committee , Research Society on Alcoholism (RSA)

2011	Search Committee , Eleanor Leslie Term Chair, UCLA Brain Research Institute
2010-2014	Awards Committee , UCLA Brain Research Institute
2009-2011	Search Committee , UCLA Learning and Behavior Area
2009-2014	Clinic Committee , UCLA Clinical Psychology Area
2008-present	Graduate Studies Committee , UCLA Psychology Department
2008-present	Diversity Committee , UCLA Psychology Department
2008-present	Admissions Committee , Clinical Psychology, UCLA Psychology Department
2006-2007	Intern Representative , Admissions Committee, Department of Psychiatry and Human Behavior, Brown Medical School

UCLA Thesis and Dissertation Committees

2015-	Chair, dissertation committee, <i>Spencer Bujarski</i> , Clinical Psychology
2014-	Chair, dissertation committee, <i>Kelly Courtney</i> , Clinical Psychology
2014-	Chair, dissertation committee, <i>Nathasha Moallem</i> , Clinical Psychology
2014-	Chair, dissertation committee, <i>Vincent Allen</i> , Clinical Psychology
2013-2014	Chair, thesis committee, <i>Emily Hartwell</i> , Clinical Psychology
2012-2014	Chair, dissertation committee, <i>Guadalupe Bacio</i> , Clinical Psychology
2012-2014	Dissertation committee, <i>Betty Liao</i> , Clinical Psychology
2012-2013	Dissertation committee, <i>Rachel Higier</i> , Clinical Psychology
2012-2014	Dissertation committee, <i>Tristen Inagaki</i> , Social Psychology
2012-2013	Thesis committee, <i>Carolyn Davies</i> , Clinical Psychology
2011-2012	Chair, thesis committee, <i>Spencer Bujarski</i> , Clinical Psychology
2010-2011	Chair, thesis committee, <i>Kelly Courtney</i> , Clinical Psychology
2010-2011	Chair, thesis committee, <i>Nathasha Moallem</i> , Clinical Psychology
2009-2013	Co-Chair, dissertation committee, <i>James Ashenhurst</i> , BRI Neuroscience Program
2011-2013	Dissertation committee, <i>Angie Morales</i> , Interdepartmental Neuroscience Program
2011-2013	Dissertation committee, <i>Amy Jimenez</i> , Clinical Psychology
2011-2013	Dissertation committee, <i>Stephanie Groman</i> , Behavioral Neuroscience
2011-2012	Dissertation committee, <i>Chris Conway</i> , Clinical Psychology
2009-2010	Chair, thesis committee, <i>Molly Tartter</i> Clinical Psychology
2010-2011	Dissertation committee, <i>Evan Lutkenhoff</i> , Interdepartmental Neuroscience Program
2009-2010	Thesis committee, <i>Alex Zvinyatskovskiy</i> , Clinical Psychology
2008-2009	Thesis committee, <i>Kate Humphreys</i> , Clinical Psychology
2009-2011	Dissertation committee, <i>Rick Laughlin</i> , Behavioral Neuroscience
2009-2011	Dissertation committee, <i>Rachael Willhite-Viehman</i> , Clinical Psychology
2009-2011	Dissertation committee, <i>Caitlin Ferriter</i> , Clinical Psychology

Professional Activities Related to Diversity

2014	Research Mentor , PROPS, UCLA Psychology Department
2013	Research Mentor , UCLA Brain Research Institute Summer Undergraduate Research Experience (BRI-SURE)
2013	Research Mentor , NIDA Summer Research Program
2012	Research Mentor , NIDA Summer Research Program
2011	Research Mentor , NIDA Summer Research Program
2010	Research Mentor , Summer Programs for Undergraduate & Graduate Research (SPUR/GR) at UCLA
2009	Research Mentor , Alliance for Graduate Education and the Professoriate (AGEP)
2003 – 2004	Doctoral Mentor , McNair Research Program, University of Colorado, Boulder
2003	Doctoral Mentor , Multicultural Access to Research Training, CU Boulder
2003	Meeting of the Society for the Advancement of Chicanos and Native Americans in Science , Albuquerque, New Mexico

2003

The Leadership Alliance Symposium, Chantilly, Virginia.

Languages Spoken

Portuguese

Spanish